戻る Agenda
Session 3a: Roadblocks and Disparities in Access of Biologics
Session Chair(s)
Tiffany Fletcher, MA
Head of Global Access Policy
Viatris, United States
Juliana Marguerite Reed, MS
Executive Director
The Biosimilars Forum, United States
This session will discuss access of biologic treatments in different geographies prior to the introduction of biosimilars and what impact biosimilars have made in conquering disparities in access to medicines and improving health equity of patients. The cost burden of chronic disease continues to grow while healthcare budgets are further constrained. Biologics treat some of the most complex diseases. In the US, for example, 40% of all drug spending if for biologic drugs, yet biologics only account for 2% of all prescriptions. Cost is one factor that contributes to disparities in access. This session will discuss access of biologic treatments in different geographies prior to the introduction of biosimilars and what impact biosimilars have made in conquering disparities in access to medicines and improving health equity of patients.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify the differences in patient access to biologics/biosimilars by region
- Identify how biosimilars have improved health equity and access to treatment for patients
- Identify how different regions implemented policies to increase patient access to these medicines
Speaker(s)
Speaker
Murray Aitken, MBA
IQVIA Institute for Human Data Science, United States
Executive Director
Speaker
Anna Hyde, MA
Arthritis Foundation, United States
Vice President of Advocacy & Access
Terry Wilcox
Patients Rising, United States
Co-Founder and CEO